Uscom Limited (AU:UCM)
ASX:UCM
Want to see AU:UCM full AI Analyst Report?
Top Page
Uscom Limited
(Sydney:UCM)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.01
▲(20.00% Upside)
Action:ReiteratedDate:10/19/25
Uscom Limited's overall stock score of 43 reflects significant challenges, primarily driven by poor financial performance with declining revenues, persistent losses, negative equity, and high leverage. Technical indicators also suggest a bearish trend despite oversold conditions, while valuation remains neutral due to negative earnings and lack of dividends. Financial health is the most critical concern for investors.
Positive Factors
Product Offering
Uscom's focus on innovative non-invasive monitoring devices, like the Uscom 1A, positions it well in the growing healthcare technology sector, providing a competitive edge in improving patient outcomes.
Negative Factors
Financial Instability
The negative equity and poor debt-to-equity ratio highlight potential solvency issues, which could limit the company's ability to invest in growth and innovation.
Read all positive and negative factors
Positive Factors
Negative Factors
Product Offering
Uscom's focus on innovative non-invasive monitoring devices, like the Uscom 1A, positions it well in the growing healthcare technology sector, providing a competitive edge in improving patient outcomes.
Read all positive factors
Uscom Limited (UCM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.12M
Dividend YieldN/A
Average Volume (3M)3.23K
Price to Earnings (P/E)―
Beta (1Y)-1.90
Revenue Growth-30.80%
EPS Growth-38.95%
CountryAU
Employees35
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)<0.01
Shares Outstanding260,147,130
10 Day Avg. Volume0
30 Day Avg. Volume3,233
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-76.24
Price to Sales (P/S)1.13
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Uscom Limited Business Overview & Revenue Model
Company Description
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; ...
How the Company Makes Money
Uscom generates revenue through the sale of its medical devices, primarily the Uscom 1A, to hospitals, clinics, and healthcare providers. The company also benefits from recurring revenue generated through service contracts, maintenance agreements,...
Uscom Limited Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
25
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.58M | 3.73M | 2.66M | 2.51M | 3.86M |
| Gross Profit | 2.23M | 3.12M | -1.03M | -1.21M | 781.70K |
| EBITDA | -3.06M | -1.51M | -2.50M | -1.84M | -833.84K |
| Net Income | -3.30M | -2.07M | -2.59M | -1.97M | -924.24K |
Balance Sheet | |||||
| Total Assets | 3.25M | 5.13M | 5.18M | 7.99M | 5.33M |
| Cash, Cash Equivalents and Short-Term Investments | 966.66K | 2.52M | 2.18M | 4.70M | 1.71M |
| Total Debt | 2.26M | 989.28K | 1.09M | 1.31M | 1.43M |
| Total Liabilities | 3.29M | 2.07M | 2.14M | 2.06M | 2.26M |
| Stockholders Equity | -38.22K | 3.06M | 3.04M | 5.94M | 3.08M |
Cash Flow | |||||
| Free Cash Flow | -2.72M | -1.22M | -1.58M | -1.08M | 21.63K |
| Operating Cash Flow | -2.71M | -1.16M | -1.42M | -967.51K | 54.98K |
| Investing Cash Flow | -68.78K | -57.55K | -151.94K | -115.31K | -33.35K |
| Financing Cash Flow | 1.21M | 1.57M | -952.96K | 4.05M | -281.87K |
Uscom Limited Technical Analysis
Negative
0.01
Price Trends
0.01
Neutral
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Negative
8.96
Positive
-66.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:UCM, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, equal to the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 8.96 is Positive, neither overbought nor oversold. The STOCH value of -66.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:UCM.
Uscom Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$3.11B | -3.16 | -890.76% | ― | 55.91% | 22.60% | |
50 Neutral | AU$657.94M | -12.03 | -109.63% | ― | -8.99% | -18.16% | |
45 Neutral | AU$30.58M | -1.41 | -165.13% | ― | 23.31% | -17.35% | |
44 Neutral | AU$91.40M | -6.27 | -54.48% | ― | 34.20% | -23.90% | |
44 Neutral | AU$2.70B | -4.94 | -152.49% | ― | ― | ― | |
43 Neutral | AU$3.12M | -0.88 | -358.43% | ― | -30.80% | -38.95% |
* Healthcare Sector Average
AU:UCM
Uscom Limited
0.01
-0.01
-52.00%
AU:IPD
Impedimed Limited
0.01
-0.02
-58.82%
AU:CYC
Cyclopharm Limited
0.71
-0.43
-38.16%
AU:4DX
4DMedical Ltd
4.76
4.48
1600.00%
AU:EBR
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
0.65
-0.58
-47.15%
AU:IMR
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
2.01
0.40
25.23%
Uscom Limited Corporate Events
Uscom Limited Announces FY2025 Results and Strategic Plans for FY2026
Nov 27, 2025
Uscom Limited, a leader in medical technology, has announced its FY2025 results and outlined drivers for FY2026. The company has achieved significant milestones, including global clinical adoption and sales in 52 countries, supported by over 1,200...
Uscom Limited Approves Disposal of Main Undertaking
Nov 7, 2025
Uscom Limited has announced the results of a recent meeting where a resolution was passed to approve the disposal of the company’s main undertaking. The resolution was decided by a poll, with 59.86% voting in favor and 40.14% voting against,...
Uscom Limited Announces Asset Sale Amid Financial Challenges
Oct 31, 2025
Uscom Limited is facing a challenging financial situation, exacerbated by global events such as COVID-19, geopolitical tensions, and trade wars, which have significantly impacted its revenue and led to consecutive years of losses. The company has ...
Uscom Limited Faces Q1 Challenges Amid Global Economic Uncertainty
Oct 31, 2025
Uscom Limited reported a challenging first quarter with a decrease in customer receipts and cash on hand, attributed to global economic uncertainties such as US tariff wars and shifts in European public spending. Despite these challenges, the comp...
Uscom Limited Announces Digital-First Annual General Meeting
Oct 27, 2025
Uscom Limited has announced its Annual General Meeting of Shareholders, scheduled for November 27, 2025, in Sydney. The company will not send physical copies of the meeting notice, opting instead for electronic distribution. Shareholders are encou...
Uscom Limited Announces 2025 AGM and Key Resolutions
Oct 27, 2025
Uscom Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 27, 2025, in Sydney. Key agenda items include the consideration of the company’s financial report for the year ending June 30, 2025, the adoption of the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.